Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom

Table 3 Drug dosages and costs (primary therapy)

Phase	Arm	Regimen	Dose	Mg per cycle^a	Vial size mg (or tablet)	Price per vial/tablet, £	Cost per cycle as per indication, £	Cost with wastage and dose reduction, £
Induction	MIDO	CYTA	200 mg/m²/day (1–7)	2660	500	£19.50	£103.74	£113.59
		DAUNO	60 mg/m²/day (1–3)	342	20	£65.00	£1111.50	£1216.61
		MIDO	50 mg (2 × 25) twice per day (8–21)	1400	25	£100.18	£6024.10	£5572.98
		Total cost per cycle					*£7239.34*	*£6903.18*
	SOC	CYTA	200 mg/m²/day (1–7)	2660	500	£19.50	£103.74	£112.68
		DAUNO	60 mg/m²/day (1–3)	342	20	£65.00	£1111.50	£1216.16
		Total cost per cycle					£1215.24	£1328.84
Consolidation	MIDO	High-dose CYTA	3000 mg/m²/day (1, 3, 5) twice/day	34,200	500	£19.50	£1333.80	£1590.36
		MIDO	50 mg (2 × 25) twice/day (8–21)	1400	25	£100.18	£6024.10	£5753.67
		Total cost per cycle					*£7357.90*	*£7344.03*
	SOC	High-dose CYTA	3000 mg/m²/day (1, 3, 5) twice/day	34,200	500	£19.50	£1333.80	£1585.32
	SOC	Total cost per cycle					£1333.80	£1585.32
Monotherapy	MIDO arm	MIDO	50 mg (2 × 25) twice/day (1–28)	2800	25	£100.18	£12,048.19	£11,596.39
Monotherapy	MIDO arm	Total cost per cycle					*£12,048.19*	*£11,596.39*

Cost source: British National Formulary and Novartis
Bold italic indicates total costs, underline indicates values belonging to the MIDO arm in each section
MIDO midostaurin, SOC standard of care, CYTA cytarabine, DAUNO daunomycin
^aMg per cycle based on a body surface area of 1.9 m² (from the RATIFY clinical trial)

ISSN: 1478-7547